GSK to move away from "industrialized" R&D
UK-based drug major GlaxoSmithKline is planning to revamp its R&D operations in an effort to expedite the creation of new and innovative medicines. In an interview with the Financial Times, the firm's head of R&D, Moncef Siaoul, said that at present "the science is overridden by managers," and that the company should move from industrialized development to more focused teams that have an increased sense of ownership of a particular project.
More collaborations and fewer tests
Mr Siaoul said that the plan was to increase the number of partnerships that GSK establishes, such as those recently signed with Galapagos, OncoMed and Santaurus (Marketletters December 5 and 11). He predicted that, within the next few years, around half of the company's drug candidates would come from external collaborations.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze